Literature DB >> 17041140

Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design.

Javier E Garcia1, Alvaro Puentes, Manuel E Patarroyo.   

Abstract

The Plasmodium falciparum sporozoite infects different types of cells in a mosquito's salivary glands and human epithelial and Kuppfer cells and hepatocytes. These become differentiated later on, transforming themselves into the invasive red blood cell form, the merozoite. The ability of sporozoites to interact with different types of cells requires a wide variety of mechanisms allowing them to survive in both hosts: mobility, receptor-ligand interactions with different cellular receptors, and transformation and development into other invasive parasite forms, which are vitally important for parasite survival. Sporozoite complexity is reflected in the large quantity of proteins that can be expressed. Some of them have been extensively studied, such as CSP, TRAP, STARP, LSA-1, LSA-3, SALSA, SPECT1, SPECT2, MAEBL, and SPATR, due to their importance in infection and their potential use as vaccines. Our work has been focused on the search for the molecular mechanisms of parasite-host cellular receptor-ligand interactions by identifying amino acid sequences and the critical binding residues from these proteins relevant to parasite invasion. Once such sequences have been identified, it will be possible to modify them to induce a strong immune response against P. falciparum in the experimental Aotus monkey model. This all leads towards developing multistage, multicomponent, subunit-based vaccines that will be effective in eradicating or controlling malaria caused by P. falciparum.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17041140      PMCID: PMC1592691          DOI: 10.1128/CMR.00063-05

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  134 in total

1.  Migration of Plasmodium sporozoites through cells before infection.

Authors:  M M Mota; G Pradel; J P Vanderberg; J C Hafalla; U Frevert; R S Nussenzweig; V Nussenzweig; A Rodríguez
Journal:  Science       Date:  2001-01-05       Impact factor: 47.728

2.  Identification, expression, and functional characterization of MAEBL, a sporozoite and asexual blood stage chimeric erythrocyte-binding protein of Plasmodium falciparum.

Authors:  Mala Ghai; Sheetij Dutta; Ted Hall; Daniel Freilich; Christian F Ockenhouse
Journal:  Mol Biochem Parasitol       Date:  2002-08-07       Impact factor: 1.759

3.  Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection.

Authors:  Katie L Flanagan; Tabitha Mwangi; Magdalena Plebanski; Kennedy Odhiambo; Amanda Ross; Eric Sheu; Moses Kortok; Brett Lowe; Kevin Marsh; Adrian V S Hill
Journal:  Am J Trop Med Hyg       Date:  2003-04       Impact factor: 2.345

4.  Sporozoite and liver stage antigen Plasmodium falciparum peptides bind specifically to human hepatocytes.

Authors:  Alvaro Puentes; Javier García; Ricardo Vera; Ramsés López; Jorge Suarez; Luis Rodríguez; Hernando Curtidor; Marisol Ocampo; Diana Tovar; Martha Forero; Adriana Bermudez; Jimena Cortes; Mauricio Urquiza; Manuel E Patarroyo
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

5.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

Authors:  K A Bojang; P J Milligan; M Pinder; L Vigneron; A Alloueche; K E Kester; W R Ballou; D J Conway; W H Reece; P Gothard; L Yamuah; M Delchambre; G Voss; B M Greenwood; A Hill; K P McAdam; N Tornieporth; J D Cohen; T Doherty
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

6.  Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

Authors:  Elizabeth H Nardin; Giane A Oliveira; J Mauricio Calvo-Calle; Kristiane Wetzel; Carolin Maier; Ashley J Birkett; Pramod Sarpotdar; Michael L Corado; George B Thornton; Annette Schmidt
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

Review 7.  How do malaria ookinetes cross the mosquito midgut wall?

Authors:  Luke A Baton; Lisa C Ranford-Cartwright
Journal:  Trends Parasitol       Date:  2005-01

8.  PfSPATR, a Plasmodium falciparum protein containing an altered thrombospondin type I repeat domain is expressed at several stages of the parasite life cycle and is the target of inhibitory antibodies.

Authors:  Rana Chattopadhyay; Dharmendar Rathore; Hishasi Fujioka; Sanjai Kumar; Patricia de la Vega; David Haynes; Kathleen Moch; David Fryauff; Ruobing Wang; Daniel J Carucci; Stephen L Hoffman
Journal:  J Biol Chem       Date:  2003-04-25       Impact factor: 5.157

9.  Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif.

Authors:  Oscar Bruna-Romero; Carolina D Rocha; Moriya Tsuji; Ricardo T Gazzinelli
Journal:  Vaccine       Date:  2004-09-09       Impact factor: 3.641

10.  Identification and chemical synthesis of a tandemly repeated immunogenic region of Plasmodium knowlesi circumsporozoite protein.

Authors:  G N Godson; J Ellis; P Svec; D H Schlesinger; V Nussenzweig
Journal:  Nature       Date:  1983 Sep 1-7       Impact factor: 49.962

View more
  9 in total

Review 1.  An epigrammatic status of the 'azole'-based antimalarial drugs.

Authors:  Mousmee Sharma; Parteek Prasher
Journal:  RSC Med Chem       Date:  2019-12-23

Review 2.  Blood coagulation, inflammation, and malaria.

Authors:  Ivo M B Francischetti; Karl B Seydel; Robson Q Monteiro
Journal:  Microcirculation       Date:  2008-02       Impact factor: 2.628

3.  Mixed allele malaria vaccines: host protection and within-host selection.

Authors:  Victoria C Barclay; Brian H K Chan; Robin F Anders; Andrew F Read
Journal:  Vaccine       Date:  2008-09-18       Impact factor: 3.641

4.  Overexpression of Plasmodium berghei ATG8 by Liver Forms Leads to Cumulative Defects in Organelle Dynamics and to Generation of Noninfectious Merozoites.

Authors:  Christiane Voss; Karen Ehrenman; Godfree Mlambo; Satish Mishra; Kota Arun Kumar; John B Sacci; Photini Sinnis; Isabelle Coppens
Journal:  MBio       Date:  2016-06-28       Impact factor: 7.867

Review 5.  Potential Sabotage of Host Cell Physiology by Apicomplexan Parasites for Their Survival Benefits.

Authors:  Shalini Chakraborty; Sonti Roy; Hiral Uday Mistry; Shweta Murthy; Neena George; Vasundhra Bhandari; Paresh Sharma
Journal:  Front Immunol       Date:  2017-10-13       Impact factor: 7.561

Review 6.  Conserved Binding Regions Provide the Clue for Peptide-Based Vaccine Development: A Chemical Perspective.

Authors:  Hernando Curtidor; César Reyes; Adriana Bermúdez; Magnolia Vanegas; Yahson Varela; Manuel E Patarroyo
Journal:  Molecules       Date:  2017-12-12       Impact factor: 4.411

7.  Variations in the electrostatic landscape of class II human leukocyte antigen molecule induced by modifications in the myelin basic protein peptide: a theoretical approach.

Authors:  William A Agudelo; Johan F Galindo; Marysol Ortiz; José L Villaveces; Edgar E Daza; Manuel E Patarroyo
Journal:  PLoS One       Date:  2009-01-09       Impact factor: 3.240

Review 8.  Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines.

Authors:  M E Patarroyo; G Cifuentes; A Bermúdez; M A Patarroyo
Journal:  J Cell Mol Med       Date:  2008-10       Impact factor: 5.310

9.  Preliminary Evaluation of the Safety and Immunogenicity of an Antimalarial Vaccine Candidate Modified Peptide (IMPIPS) Mixture in a Murine Model.

Authors:  Jennifer Lambraño; Hernando Curtidor; Catalina Avendaño; Diana Díaz-Arévalo; Leonardo Roa; Magnolia Vanegas; Manuel E Patarroyo; Manuel A Patarroyo
Journal:  J Immunol Res       Date:  2019-12-30       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.